Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Current Deferred Revenue (2023 - 2025)

Entrada Therapeutics (TRDA) has 3 years of Current Deferred Revenue data on record, last reported at $342000.0 in Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 97.5% year-over-year to $342000.0; the TTM value through Dec 2025 reached $342000.0, down 97.5%, while the annual FY2025 figure was $342000.0, 97.5% down from the prior year.
  • Current Deferred Revenue reached $342000.0 in Q4 2025 per TRDA's latest filing, up from $113000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $122.3 million in Q1 2023 and bottomed at $113000.0 in Q3 2025.
  • Average Current Deferred Revenue over 3 years is $27.0 million, with a median of $9.9 million recorded in 2024.
  • Peak YoY movement for Current Deferred Revenue: surged 337.07% in 2024, then plummeted 99.75% in 2025.
  • A 3-year view of Current Deferred Revenue shows it stood at $7.7 million in 2023, then surged by 76.98% to $13.7 million in 2024, then plummeted by 97.5% to $342000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $342000.0 in Q4 2025, $113000.0 in Q3 2025, and $194000.0 in Q2 2025.